MRKR

Clinical Study Results: The APOLLO study reported a 66% objective response rate and a 50% complete response rate for MT-601 in relapsed Non-Hodgkin lymphoma patients, demonstrating a favorable safety profile with no dose-limiting toxicities observed.

New Treatment Initiatives: Marker Therapeutics treated the first patient in the RAPID study, exploring Off-the-Shelf MAR-T cells for Acute Myeloid Leukemia and Myelodysplastic Syndrome, while also launching a clinical program for MT-601 in metastatic pancreatic cancer.

Manufacturing Collaboration: The company established a cGMP manufacturing partnership with Cellipont Bioservices to enhance production capabilities for MT-601, supporting clinical supply and future pivotal trials.

Financial Position: Marker Therapeutics raised approximately $10 million, extending its cash runway into 2026, with a reported net loss of $2 million for the third quarter of 2025, reflecting a decrease in research and development expenses compared to the previous year.

Study Overview: The Phase 1 APOLLO study is investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell therapy, in patients with relapsed B cell lymphomas, showing promising preliminary efficacy data with an objective response rate of 66% in Non-Hodgkin lymphoma and 78% in Hodgkin lymphoma.

Safety Profile: MT-601 demonstrated a robust safety profile with no dose limiting toxicities or immune-effector cell associated neurotoxicity syndrome reported, and only two participants experienced mild cytokine release syndrome.

Upcoming Presentations: Data from the APOLLO study will be presented in two posters at the 67th American Society of Hematology Annual Meeting from December 6-9, 2025, highlighting the safety and efficacy of MT-601 in relapsed or refractory lymphomas.

Company Background: Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based therapies for hematological malignancies and solid tumors, with a commitment to operational excellence and patient outcome improvement.

Clinical Study Update: Marker Therapeutics provided an update on the Phase 1 APOLLO study of MT-601, a MAR-T cell product for lymphoma patients who have relapsed after anti-CD19 CAR-T therapy or are not eligible for it.

Efficacy Results: The study reported a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving complete responses. Hodgkin Lymphoma (HL) patients showed a 78% response rate, indicating MT-601's effectiveness across different lymphoma types.

Safety Profile: No dose-limiting toxicities were observed at the highest dose tested, and the treatment was well tolerated with minimal adverse events, including only two Grade 1 cytokine release syndrome cases.

Future Updates: Marker Therapeutics plans to provide additional data updates in the first half of 2026, while their stock price has seen a decline of 14.28% to $1.08 at the time of publication.